热门资讯> 正文
施罗德因放弃白血病候选药物而下降16%
2025-08-14 20:55
- Schrodinger (NASDAQ:SDGR) has fallen ~16% in premarket trading Thursday after announcing it would end development of SGR-2921 for relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes following the deaths of two AML patients in a trial.
- The CDC7 inhibitor was in a phase 1 dose escalation study.
- The company said that there were "two emergent events where SGR-2921 was considered to have contributed to two deaths in patients with AML." As a result, further development as a combination treatment "would be difficult to pursue."
More on Schrödinger
- Schrödinger, Inc. 2025 Q2 - Results - Earnings Call Presentation
- Schrödinger, Inc. (SDGR) Q2 2025 Earnings Call Transcript
- Schrödinger: Assessing The Signal And The Noise In The Phase 1 Results
- Schrödinger maintains 10–15% software revenue growth guidance while advancing SGR-1505 clinical program
- Schrödinger Q2 2025 Earnings Preview
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
